Armata Pharmaceuticals, Inc.
NYSE American ARMP
Armata Pharmaceuticals, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 29.23
-
Armata Pharmaceuticals, Inc. 52-week high Price to Sales Ratio (P/S) is 39.90 on November 12, 2024, which is 36.48% above the current Price to Sales Ratio (P/S).
-
Armata Pharmaceuticals, Inc. 52-week low Price to Sales Ratio (P/S) is 18.45 on May 01, 2024, which is -36.88% below the current Price to Sales Ratio (P/S).
-
Armata Pharmaceuticals, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 27.23.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Dr. Deborah L. Birx M.D. |
| IPO Date | May 20, 1994 |
| Location | United States |
| Headquarters | 4503 Glencoe Avenue |
| Employees | 66 |
| Sector | Health Care |
| Industries | |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Past 5 years
USD 2.13
StockViz Staff
January 15, 2025
Any question? Send us an email